Neurobiological Technologies (Neurobiological Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2009)

View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies COGS-to-Revenue?

Neurobiological Technologies's Cost of Goods Sold for the three months ended in Sep. 2009 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2009 was $6.03 Mil.

Neurobiological Technologies's COGS to Revenue for the three months ended in Sep. 2009 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Neurobiological Technologies's Gross Margin % for the three months ended in Sep. 2009 was N/A%.

Neurobiological Technologies COGS-to-Revenue Historical Data

The historical data trend for Neurobiological Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies COGS-to-Revenue Chart

Neurobiological Technologies Annual Data

Trend

Jun00

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

COGS-to-Revenue

Get a 7-Day Free Trial

Neurobiological Technologies Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Neurobiological Technologies COGS-to-Revenue Calculation

Neurobiological Technologies's COGS to Revenue for the fiscal year that ended in Jun. 2009 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	26.35
	=	0.00

Neurobiological Technologies's COGS to Revenue for the quarter that ended in Sep. 2009 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	6.026
	=	0.00

Neurobiological Technologies (OTCPK:NTII) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Neurobiological Technologies's Gross Margin % for the three months ended in Sep. 2009 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 6.026
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Neurobiological Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583

Website

http://www.ntii.com

Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Executives

Ariel Warszawski	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp	10 percent owner	426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp	10 percent owner	FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin	director
Abraham E Cohen	director	500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer	director	HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc	other: Direct Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines

From GuruFocus

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 05-09-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-12-2010

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 02-12-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009